Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection

Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection

Abstract Background The number of pneumocystis pneumonia (PCP) cases is increasing in immunocompromised patients without human immunodeficiency virus infection (HIV), causing serious morbidity with high mortality. Trimethoprim/sulfamethoxazole (TMP/SMZ) monotherapy has limited effectiveness in the t...

Full description

Bibliographic Details
Main Authors: Hui Qi, Danjiang Dong, Ning Liu, Ying Xu, Mengzhi Qi, Qin Gu
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Infectious Diseases
Subjects:
Pneumocystis pneumonia
Trimethoprim–sulfamethoxazole
Caspofungin
Combination therapy
Online Access:https://doi.org/10.1186/s12879-023-08372-z

Internet

https://doi.org/10.1186/s12879-023-08372-z

Similar Items